21st.BIO specializes in delivering precision fermentation technology to accelerate the production of sustainable proteins and peptides. Their platform bridges the gap between lab innovation and industrial-scale manufacturing, leveraging expertise from Novo Nordisk and Novonesis. They offer shared development programs for nature-identical molecules and bespoke projects for exclusive protein assets, enabling faster, lower-risk market entry for partners.
Bevorzugte Reifephase für die erste Finanzierung.
Precision fermentation technology platform for proteins and peptides, enabling scalable biomanufacturing
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...